Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more
Sopharma AD (SPH) - Net Assets
Latest net assets as of September 2025: zł981.36 Million PLN
Based on the latest financial reports, Sopharma AD (SPH) has net assets worth zł981.36 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł2.02 Billion) and total liabilities (zł1.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł981.36 Million |
| % of Total Assets | 48.63% |
| Annual Growth Rate | 6.63% |
| 5-Year Change | 48.8% |
| 10-Year Change | 84.23% |
| Growth Volatility | 4.77 |
Sopharma AD - Net Assets Trend (2011–2024)
This chart illustrates how Sopharma AD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sopharma AD (2011–2024)
The table below shows the annual net assets of Sopharma AD from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł843.10 Million | +11.87% |
| 2023-12-31 | zł753.63 Million | +4.94% |
| 2022-12-31 | zł718.13 Million | +8.99% |
| 2021-12-31 | zł658.87 Million | +16.29% |
| 2020-12-31 | zł566.60 Million | -1.59% |
| 2019-12-31 | zł575.77 Million | +13.22% |
| 2018-12-31 | zł508.53 Million | +1.08% |
| 2017-12-31 | zł503.11 Million | +2.42% |
| 2016-12-31 | zł491.22 Million | +7.34% |
| 2015-12-31 | zł457.64 Million | +6.02% |
| 2014-12-31 | zł431.64 Million | +4.57% |
| 2013-12-31 | zł412.77 Million | +5.47% |
| 2012-12-31 | zł391.35 Million | +6.98% |
| 2011-12-31 | zł365.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sopharma AD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 330.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł665.36 Million | 80.75% |
| Common Stock | zł179.10 Million | 21.74% |
| Other Comprehensive Income | zł33.02 Million | 4.01% |
| Total Equity | zł823.92 Million | 100.00% |
Sopharma AD Competitors by Market Cap
The table below lists competitors of Sopharma AD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BrainChip Holdings Ltd
OTCQX:BCHPY
|
$244.10 Million |
|
Hong Leong Industries Bhd
KLSE:3301
|
$244.14 Million |
|
Shandong Daye Co Ltd Class A
SHG:603278
|
$244.22 Million |
|
China Youzan Ltd
PINK:CHNVF
|
$244.32 Million |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
$244.02 Million |
|
W&T Offshore Inc
NYSE:WTI
|
$243.99 Million |
|
INOX India Limited
NSE:INOXINDIA
|
$243.96 Million |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
$243.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sopharma AD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 738,332,000 to 823,919,000, a change of 85,587,000 (11.6%).
- Net income of 76,310,000 contributed positively to equity growth.
- Dividend payments of 168,435,000 reduced retained earnings.
- Share repurchases of 7,000 reduced equity.
- New share issuances of 32,640,000 increased equity.
- Other comprehensive income decreased equity by 10,029,001.
- Other factors increased equity by 155,108,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł76.31 Million | +9.26% |
| Dividends Paid | zł168.44 Million | -20.44% |
| Share Repurchases | zł7.00K | -0.0% |
| Share Issuances | zł32.64 Million | +3.96% |
| Other Comprehensive Income | zł-10.03 Million | -1.22% |
| Other Changes | zł155.11 Million | +18.83% |
| Total Change | zł- | 11.59% |
Book Value vs Market Value Analysis
This analysis compares Sopharma AD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.05x to 1.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | zł2.46 | zł7.50 | x |
| 2012-12-31 | zł2.69 | zł7.50 | x |
| 2013-12-31 | zł2.82 | zł7.50 | x |
| 2014-12-31 | zł2.93 | zł7.50 | x |
| 2015-12-31 | zł3.14 | zł7.50 | x |
| 2016-12-31 | zł3.55 | zł7.50 | x |
| 2017-12-31 | zł3.74 | zł7.50 | x |
| 2018-12-31 | zł3.78 | zł7.50 | x |
| 2019-12-31 | zł4.42 | zł7.50 | x |
| 2020-12-31 | zł4.40 | zł7.50 | x |
| 2021-12-31 | zł5.16 | zł7.50 | x |
| 2022-12-31 | zł5.81 | zł7.50 | x |
| 2023-12-31 | zł5.31 | zł7.50 | x |
| 2024-12-31 | zł5.00 | zł7.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sopharma AD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.58%
- • Asset Turnover: 1.19x
- • Equity Multiplier: 2.18x
- Recent ROE (9.26%) is below the historical average (9.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 12.00% | 5.96% | 0.95x | 2.11x | zł6.40 Million |
| 2012 | 10.18% | 5.11% | 0.92x | 2.16x | zł608.10K |
| 2013 | 8.16% | 3.83% | 0.97x | 2.18x | zł-6.61 Million |
| 2014 | 5.43% | 2.40% | 1.03x | 2.20x | zł-16.95 Million |
| 2015 | 5.25% | 2.44% | 1.05x | 2.06x | zł-19.28 Million |
| 2016 | 11.07% | 5.77% | 1.02x | 1.88x | zł4.89 Million |
| 2017 | 8.51% | 3.93% | 1.04x | 2.09x | zł-6.99 Million |
| 2018 | 5.96% | 2.40% | 1.17x | 2.13x | zł-19.21 Million |
| 2019 | 15.63% | 6.79% | 1.09x | 2.11x | zł31.35 Million |
| 2020 | 5.39% | 2.07% | 1.16x | 2.25x | zł-25.52 Million |
| 2021 | 13.83% | 5.58% | 1.33x | 1.86x | zł24.80 Million |
| 2022 | 10.07% | 4.28% | 1.32x | 1.78x | zł513.70K |
| 2023 | 12.89% | 5.04% | 1.25x | 2.05x | zł21.37 Million |
| 2024 | 9.26% | 3.58% | 1.19x | 2.18x | zł-6.08 Million |
Industry Comparison
This section compares Sopharma AD's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $467,421,000
- Average return on equity (ROE) among peers: 19.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sopharma AD (SPH) | zł981.36 Million | 12.00% | 1.06x | $244.08 Million |
| Neuca S.A. (NEU) | $467.42 Million | 19.91% | 4.50x | $279.51 Million |